View Older Stories View More Recent Stories
-
Humana (HUM) PT Lowered to $253 at Jefferies
-
Humana (HUM) Tops Q3 EPS by 41c; affirms guidance
-
Important Notice Long-Term Shareholders of Humana Inc. (HUM): Grabar Law Office Investigates Claims on Your Behalf
-
Humana expands veteran-focused Medicare plans with free mental health care
-
Humana announces 2026 Medicare plans for veterans with mental health focus
-
Goldman Sachs Starts Humana (HUM) at Sell
-
Humana Loses Second Lawsuit To Reverse Medicare Bonus Cuts - Bloomberg
-
Cantor Fitzgerald Reiterates Neutral on Humana (HUM), Notes 2026 MA Margin Improvement
-
Cantor Fitzgerald Reiterates Neutral on Molina Healthcare (MOH), Highlights 2026 Stars Progress
-
Mizuho Positive on CVS Health (CVS): 'We believe this is a positive for CVS'
-
Humana (HUM) PT Raised to $313 at Wolfe Research
-
Humana maintains 2025 earnings guidance amid Medicare star ratings update
-
Humana announces 2026 Medicare Advantage plan changes
-
Cantor Fitzgerald Reiterates Neutral Rating on Humana (HUM)
-
Trump: Working On Lowering Cost Of Health Insurance
-
Evercore ISI Starts Humana (HUM) at In Line, PT $295, 'Counting Dollars, Counting Stars'
-
Raymond James Defending on Humana (HUM), PT $340: 'we think the recent pullback creates an attractive entry point into the stock'
-
UnitedHealth projects most Medicare Advantage members in top-rated plans by 2027
-
Humana expands musculoskeletal care with Vori Health and HOPCo partnerships
-
Humana (HUM) PT Raised to $322 at RBC Capital
-
UnitedHealth Group (UNH), Humana (HUM), Others Climb
-
Raymond James on Humana (HUM): 'Medicaid Fears Didn't Surface, and Core Guide Raise Better Than It Appears'
-
Humana (HUM) Tops Q2 EPS by 40c; raises guidance
-
Humana to eliminate one-third of prior authorizations by 2026
-
UBS Reiterates Neutral Rating on Humana (HUM)
-
Guggenheim Reiterates Buy Rating on Humana (HUM)
-
Morgan Stanley Reiterates Equalweight Rating on Humana (HUM)
-
Leerink Partners Reiterates Market Perform Rating on Humana (HUM)
-
Raymond James Reiterates Outperform Rating on Humana (HUM)
-
Mizuho weighs in on Humana (HUM) after it lost MA stars lawsuit
-
Barclays Comments on Humana (HUM) Dismissal
-
Texas Judge dismisses Humana (HUM) challenge to Medicare quality bonus payment for 2026 - court document
-
Humana stock falls after losing Medicare bonus payment lawsuit
-
Humana (HUM) Loses Medicare Bonus Payment Lawsuit - Bloomberg
-
Humana (HUM) Launches Medicaid Plan in Virginia
-
Centene (CNC) PT Lowered to $52 at BofA Securities
-
Humana (HUM) Healthcare stocks on watch after Centene withdraws guidance
-
Humana (HUM) PT Raised to $340 at Raymond James
-
Humana (HUM) expands SBT with SBTi initiative
-
Health Insurers To Promise Changes To Preapproval Process - WSJ
-
Bernstein on Humana (HUM): 'We Are Positive on the Sector Turnaround Opportunities'
-
TD Cowen Reiterates Hold Rating on Humana (HUM)
-
RBC Capital on Humana (HUM): 'Multiple Levers To Drive Strong EPS Growth Expected By 2028'
-
Humana (HUM) PT Lowered to $280 at Truist Securities
-
UBS Reiterates Neutral Rating on Humana (HUM)
-
UBS Reiterates Neutral Rating on Humana (HUM)
-
Mizuho Reiterates Outperform Rating on Humana (HUM)
-
Cantor Fitzgerald Reiterates Neutral Rating on Humana (HUM)
-
Humana (HUM) Planning Business Assuming They Lose Stars Lawsuit: CEO - Bloomberg
-
Bernstein's Expectations for Humana (HUM) Ahead of Investor Day
